sorafenib has been researched along with Rhabdomyosarcoma in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dolgikh, N; Fulda, S | 1 |
| Blaney, SM; Fox, E; Jayaprakash, N; Kim, A; Krailo, M; Weigel, B; Widemann, BC | 1 |
1 trial(s) available for sorafenib and Rhabdomyosarcoma
| Article | Year |
|---|---|
Phase 2 trial of sorafenib in children and young adults with refractory solid tumors: A report from the Children's Oncology Group.
Topics: Adolescent; Angiogenesis Inhibitors; Antineoplastic Agents; Child; Child, Preschool; Female; Humans; Kidney Neoplasms; Male; Neoplasm Proteins; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Rhabdomyosarcoma; Salvage Therapy; Sorafenib; Treatment Failure; Vascular Endothelial Growth Factor A; Vascular Endothelial Growth Factor Receptor-2; Wilms Tumor; Young Adult | 2015 |
1 other study(ies) available for sorafenib and Rhabdomyosarcoma
| Article | Year |
|---|---|
Rhabdomyosarcoma cells are susceptible to cell death by LDK378 alone or in combination with sorafenib independently of anaplastic lymphoma kinase status.
Topics: Anaplastic Lymphoma Kinase; Animals; Antineoplastic Combined Chemotherapy Protocols; Cell Death; Cell Line, Tumor; Drug Synergism; Humans; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyrimidines; Receptor Protein-Tyrosine Kinases; Rhabdomyosarcoma; Sorafenib; Sulfones | 2017 |